The U.S. Food and Drug Administration late Monday authorized the emergency use of Pfizer Inc.
PFE,
and BioNTech SE
BNTX,
COVID-19 vacccine for children between the ages of 12 and 15. Acting FDA commissioner Janet Woodcock called the expansion of the emergency use a “significant step in the fight against the COVID-19 pandemic.” The FDA had granted the vaccine emergency use for people 16 and older. “Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations,” she said. From March 2020 through April 2021, about 1.5 million COVID-19 cases in kids 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention, the FDA said.
The U.S. Food and Drug Administration late Monday authorized the emergency use of Pfizer Inc.
PFE,
and BioNTech SE
BNTX,
COVID-19 vacccine for children between the ages of 12 and 15. Acting FDA commissioner Janet Woodcock called the expansion of the emergency use a “significant step in the fight against the COVID-19 pandemic.” The FDA had granted the vaccine emergency use for people 16 and older. “Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations,” she said. From March 2020 through April 2021, about 1.5 million COVID-19 cases in kids 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention, the FDA said.